KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Leases (2019 - 2025)

AbbVie has reported Leases over the past 7 years, most recently at $737.0 million for Q4 2025.

  • Quarterly Leases rose 2133.33% to $737.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $737.0 million through Dec 2025, up 2133.33% year-over-year, with the annual reading at $737.0 million for FY2025, 2133.33% up from the prior year.
  • Leases was $737.0 million for Q4 2025 at AbbVie, up from $33.0 million in the prior quarter.
  • Over five years, Leases peaked at $762.0 million in Q4 2021 and troughed at $25.0 million in Q4 2022.
  • The 5-year median for Leases is $737.0 million (2025), against an average of $460.2 million.
  • Year-over-year, Leases tumbled 96.72% in 2022 and then surged 2876.0% in 2023.
  • A 5-year view of Leases shows it stood at $762.0 million in 2021, then tumbled by 96.72% to $25.0 million in 2022, then surged by 2876.0% to $744.0 million in 2023, then crashed by 95.56% to $33.0 million in 2024, then surged by 2133.33% to $737.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Leases are $737.0 million (Q4 2025), $33.0 million (Q4 2024), and $744.0 million (Q4 2023).